| Literature DB >> 23043420 |
Guido Furlotti1, Maria Alessandra Alisi, Claudia Apicella, Alessandra Capezzone de Joannon, Nicola Cazzolla, Roberta Costi, Giuliana Cuzzucoli Crucitti, Beatrice Garrone, Alberto Iacovo, Gabriele Magarò, Giorgina Mangano, Gaetano Miele, Rosella Ombrato, Luca Pescatori, Lorenzo Polenzani, Federica Rosi, Marco Vitiello, Roberto Di Santo.
Abstract
Since the discovery of the serotonin 4 receptor (5-HT(4)R), a large number of receptor ligands have been studied. The safety concerns and the lack of market success of these ligands have mainly been attributed to their lack of selectivity. In this study we describe the discovery of N-[(4-piperidinyl)methyl]-1H-indazole-3-carboxamide and 4-[(4-piperidinyl)methoxy]-2H-pyrrolo[3,4-c]quinoline derivatives as new 5-HT(4)R ligands endowed with high selectivity over the serotonin 2A receptor and human ether-a-go-go-related gene potassium ion channel. Within these series, two molecules (11 ab and 12 g) were identified as potent and selective 5-HT(4)R antagonists with good in vitro pharmacokinetic properties. These compounds were evaluated for their antinociceptive action in two analgesia animal models. 12 g showed a significant antinociceptive effect in both models and is proposed as an interesting lead compound as a 5-HT(4)R antagonist with analgesic action.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23043420 DOI: 10.1021/jm300573d
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446